109 related articles for article (PubMed ID: 11798143)
21. Encapsulating peritoneal sclerosis in patients on peritoneal dialysis.
Hendriks MP; de Sévaux RG; Hilbrands LB
Neth J Med; 2008; 66(7):269-74. PubMed ID: 18663253
[TBL] [Abstract][Full Text] [Related]
22. Sclerosing encapsulating peritonitis secondary to CAPD: the effect of fibrotic debridement on further dialysis.
Klimopoulos S; Katsoulis IE; Margellos V; Nikolopoulou N
J R Coll Surg Edinb; 2002 Apr; 47(2):485-90. PubMed ID: 12018692
[TBL] [Abstract][Full Text] [Related]
23. Pathogenic significance of hypertrophic mesothelial cells in peritoneal effluent and ex vivo culture.
Bajo MA; del Peso G; Castro MA; Cirugeda A; Castro MJ; Olea T; Costero O; Sánchez-Tomero JA; Díaz C; Selgas R
Adv Perit Dial; 2004; 20():43-6. PubMed ID: 15384793
[TBL] [Abstract][Full Text] [Related]
24. Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients.
Alscher DM; Braun N; Biegger D; Fritz P
Am J Kidney Dis; 2007 Mar; 49(3):452-61. PubMed ID: 17336707
[TBL] [Abstract][Full Text] [Related]
25. [Encapsulating peritoneal sclerosis].
Fantová L; Safárová R; Vanková S
Vnitr Lek; 2007 Feb; 53(2):164-8. PubMed ID: 17419179
[TBL] [Abstract][Full Text] [Related]
26. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Bozkurt D; Taskin H; Sezak M; Biçak S; Sen S; Ok E; Duman S
Adv Perit Dial; 2008; 24():32-8. PubMed ID: 18985998
[TBL] [Abstract][Full Text] [Related]
27. Omental milky spots and peritoneal dialysis--review and personal experience.
Di Paolo N; Sacchi G; Garosi G; Sansoni E; Bargagli L; Ponzo P; Tanganelli P; Gaggiotti E
Perit Dial Int; 2005; 25(1):48-57. PubMed ID: 15770926
[TBL] [Abstract][Full Text] [Related]
28. Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model.
Mizuno M; Ito Y; Hepburn N; Mizuno T; Noda Y; Yuzawa Y; Harris CL; Morgan BP; Matsuo S
J Immunol; 2009 Jul; 183(2):1403-12. PubMed ID: 19553534
[TBL] [Abstract][Full Text] [Related]
29. Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery.
Kawanishi H; Moriishi M; Tsuchiya S
Adv Perit Dial; 2006; 22():60-4. PubMed ID: 16983941
[TBL] [Abstract][Full Text] [Related]
30. Fibrin degradation products are a useful marker for the risk of encapsulating peritoneal sclerosis.
Moriishi M; Kawanishi H
Adv Perit Dial; 2008; 24():56-9. PubMed ID: 18986002
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with tamoxifen in peritoneal fibrosing syndromes.
del Peso G; Bajo MA; Gil F; Aguilera A; Ros S; Costero O; Castro MJ; Selgas R
Adv Perit Dial; 2003; 19():32-5. PubMed ID: 14763031
[TBL] [Abstract][Full Text] [Related]
32. Sclerosing encapsulating peritonitis (abdominal cocoon) associated with liver cirrhosis and diffuse large B-cell lymphoma: autopsy case.
Yamada S; Tanimoto A; Matsuki Y; Hisada Y; Sasaguri Y
Pathol Int; 2009 Sep; 59(9):681-6. PubMed ID: 19712139
[TBL] [Abstract][Full Text] [Related]
33. Intestinal obstruction due to idiopathic sclerosing encapsulating peritonitis. Clinical report and review of literature.
Minutolo V; Gagliano G; Angirillo G; Minutolo O; Morello A; Rinzivillo C
G Chir; 2008 Apr; 29(4):173-6. PubMed ID: 18419984
[TBL] [Abstract][Full Text] [Related]
34. [Encapsulating peritoneal sclerosis--a serious complication of peritoneal dialysis with not characteristic symptoms].
Kowalewska J; Lichodziejewska-Niemierko M; Liberek T; Mechlińska-Baczkowska J; Nałecz A; Jaśkiewicz K; Rutkowski B
Wiad Lek; 2006; 59(5-6):419-21. PubMed ID: 17017495
[TBL] [Abstract][Full Text] [Related]
35. [Morpho-functional study of peritoneum in peritoneal dialysis].
Bertoli SV; Buzzi L; Ciurlino D; Maccario M; Martino S
G Ital Nefrol; 2003; 20(2):160-5. PubMed ID: 12746801
[TBL] [Abstract][Full Text] [Related]
36. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.
Duman S; Bozkurt D; Sipahi S; Sezak M; Ozkan S; Ertilav M; Sen S; Ok E
Adv Perit Dial; 2008; 24():104-10. PubMed ID: 18986012
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal permeability in patients with encapsulating peritoneal sclerosis.
Fang CC; Tsai TJ
Am J Kidney Dis; 2006 Nov; 48(5):875; author reply 875-6. PubMed ID: 17060010
[No Abstract] [Full Text] [Related]
38. Sclerosing encapsulating peritonitis in an anti-HCV-positive patient on chronic ambulatory peritoneal dialysis.
Dogan E; Ucmak H; Sayarlioglu H; Sahin M; Ucar MA; Gunduz M
Ren Fail; 2007; 29(6):777-8. PubMed ID: 17763180
[No Abstract] [Full Text] [Related]
39. Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats.
Zareie M; Keuning ED; ter Wee PM; Beelen RH; van den Born J
Nephrol Dial Transplant; 2005 Jan; 20(1):189-93. PubMed ID: 15572385
[TBL] [Abstract][Full Text] [Related]
40. [Sclerosing peritonitis with a predominant inflammatory component after fungal peritonitis].
Lentisco CR; Gallar PR; Ortiz ML; Ortega OM
Nefrologia; 2008; 28(4):469-70. PubMed ID: 18662165
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
